Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics (Nasdaq: LXEO) launched a primary offering of 15,625,000 shares of common stock at $8.00 per share, generating gross proceeds of $125.0 million, less $0.48 per share in underwriting discounts. The company also entered a concurrent private placement of pre-funded warrants to purchase 1,250,015 shares for approximately $10.0 million at $7.9999 per warrant. The underwriters have a 30-day option to purchase up to 2,343,750 additional shares at the public price, less discounts.
Lexeo estimates net proceeds of approximately $126.2 million from the offering and concurrent private placement, or approximately $143.8 million if the option is exercised in full, to support operations and development plans. As context, cash, cash equivalents and investments were $122.8 million as of September 30, 2025. Shares outstanding were 54,001,214 as of June 30, 2025.
Lexeo Therapeutics (LXEO) filed a preliminary prospectus supplement for a primary offering of common stock and pre-funded warrants. The pre-funded warrants carry a $0.0001 exercise price, do not expire, and are offered in lieu of shares to certain investors subject to 4.99% or 9.99% beneficial ownership limits. The filing includes a 30‑day underwriters’ option to purchase additional shares.
A concurrent private placement is contemplated with Balyasny Asset Management at the public offering price, contingent on the closing of this offering. Lexeo’s common stock last closed at $8.83 on October 15, 2025, and 54,001,214 shares were outstanding as of June 30, 2025.
Operational updates: the company reported preliminary cash, cash equivalents and investments of $122.8 million as of September 30, 2025. For LX2006 (FA cardiomyopathy), the FDA indicated openness to an accelerated approval BLA using pooled data with enhanced manufacturing comparability for the planned pivotal study. LX2020 (PKP2-ACM) has dosed nine participants across dose cohorts with ongoing safety and efficacy assessments.
Lexeo Therapeutics, Inc. reported regulatory updates and clinical progress for its gene therapy candidate LX2006 for Friedreich ataxia cardiomyopathy. The company received FDA feedback on key components of a potential accelerated approval pathway for LX2006 and highlighted positive interim Phase 1/2 clinical data in this indication. On October 7, 2025, Lexeo issued a press release detailing these developments and scheduled a conference call and webcast at 8:00 a.m. ET the same day to discuss the regulatory updates and interim data. The corporate presentation and press release are furnished as exhibits to provide more detail on the program and pathway.
Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), reported an acquisition of common stock on 09/12/2025 under the companys 2023 Employee Stock Purchase Plan. The Form 4 shows the purchase of 2,193 shares at a price of $2.644 per share. After this transaction, the reporting person beneficially owns 222,251 shares in total, a position that explicitly includes 131,092 Restricted Stock Units.
The filing is executed by an attorney-in-fact and states the ESPP transaction is exempt under Rule 16b-3(c) and 16b-3(d). No derivative transactions or other disposals are reported on this Form 4.
Richard N. Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), amended a Form 4 to correct previously reported insider sales. The amendment states that on 08/18/2025 Townsend disposed of 1,115 shares of Common Stock at a price of $4.668 per share to cover tax obligations arising from the release of restricted stock units (RSUs). After the reported disposition, Townsend beneficially owned 220,058 shares, which include 131,092 RSUs. The amended filing clarifies an earlier filing that had incorrectly reported a disposition of 2,735 shares. The amendment is signed by an attorney-in-fact on behalf of the reporting person.
Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics, acquired equity awards in the issuer. The Form 4 reports receipt of 45,000 restricted stock units (RSUs), each convertible into one share, and a stock option to purchase 280,000 shares at an exercise price of $4.79 per share. The RSUs carry no cash price and vest over time: 25% vest on August 15, 2026, with the remainder vesting in periodic installments thereafter under the company’s standard schedule. The option has a 10-year contractual term expiring August 28, 2035, with 25% of the option shares vesting on August 15, 2026, and the rest vesting monthly in equal installments thereafter, all subject to continued service. After these reported transactions, the filing shows 45,000 shares beneficially owned from RSUs and 280,000 option shares outstanding.
Lexeo Therapeutics reported an initial Section 16 Form 3 for Louis Edward Tamayo, who is identified as Chief Financial Officer and an officer/director of the company. The form, with an event date of 08/15/2025, shows no securities beneficially owned by the reporting person at the time of filing. The filing was signed by an attorney-in-fact on 08/27/2025.
Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics (LXEO), reported a sale of 2,848 shares of common stock on 08/18/2025 at a price of $4.668 per share to cover tax obligations arising from the release of restricted stock units (RSUs). After the reported transaction, he beneficially owns 60,372 shares, which include 49,687 RSUs. The filing identifies the transaction as a sale to cover taxes on RSU vesting and was submitted under a single reporting person designation. The form is signed by an attorney-in-fact on behalf of the reporting person.
Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics, Inc. (LXEO), reported on a Form 4 that she sold 542 shares of the company's common stock on 08/18/2025 at a reported price of $4.668 per share. The filing states this sale was made to cover tax obligations arising from the release of restricted stock units (RSUs). After the transaction, Robertson beneficially owned 62,556 shares in total, which the filing clarifies includes 51,092 RSUs. The Form 4 was signed by an attorney-in-fact, Youjin Choi, on 08/20/2025.
Eric Adler, Chief Medical Officer of Lexeo Therapeutics, Inc. (LXEO), reported a transaction dated 08/18/2025 on Form 4 showing a sale of 608 shares of Common Stock at $4.668 per share. The filing explains the sale was to cover tax obligations on the release of restricted stock units (RSUs). Following the reported transaction, Adler beneficially owns 67,073 shares, which the filing notes includes 60,546 RSUs. The form was executed by an attorney-in-fact on 08/20/2025. The filing discloses the insider relationship and provides the required Section 16 reporting information.